Singapore market entry: three Korean deep-tech firms seek a first reference customer
Three Korean technology companies supported by the Incheon Center for Creative Economy & Innovation (Incheon CCEI) will visit Singapore from 26 to 29 October 2026 to meet potential customers, pilot partners and ecosystem stakeholders. The three — IDCITI, DeepCardio and JCHI Global — span positioning, healthcare and advanced materials. Singapore-headquartered business builder KILSA Global is facilitating their market entry and partner matching.
The release discloses no signed partnership, no deal value and no named Singapore partner. It describes a delegation, not a transaction. What makes it worth reading is what it says about how Korean deep-tech reaches ASEAN — and the specific gap all three companies are trying to close: they have products validated in Korea and no Singapore customer to point to. For the companies, Singapore market entry is a deliberate first step rather than a destination: a small, regulated, English-speaking market that many Southeast Asian buyers treat as a reference. Prove it in Singapore, the logic goes, and the rest of the region follows.
The market-entry model
KILSA Global, founded in 2015, runs what it calls a “Global Business Builder” model: market validation, local business development, partner matching, proof-of-concept development and on-the-ground execution, with offices across Southeast Asia and Korea. Incheon CCEI, a public startup-support organisation, runs the “BiiG WAVE Global” market-entry programme; the Singapore cohort is the vehicle for this visit.
The model is a familiar one for cross-border deep-tech. Singapore market entry is also a specific discipline. A company must satisfy local procurement, regulatory and standards expectations, find a partner willing to run a pilot, and show that a product validated in a temperate home market performs under tropical conditions. That is why the programme pairs readiness work — business reviews, partner outreach — with the on-site visit, rather than treating the trip as a sales pitch. A company with a validated product in its home market faces a choice: build overseas from scratch, or use a local partner that already knows the buyers. KILSA’s pitch is the second, and Singapore is the gateway because its procurement, regulation and English-language business environment make it the natural first market for ASEAN expansion.
One caveat worth noting: the release names three companies, while KILSA’s own promotional material for a late-October Singapore entry programme referenced seven Korean founders. The two figures are not reconciled, so read the cohort size with care.
IDCITI: positioning where GPS fails
IDCITI’s technology, uGPS, regenerates synchronised satellite-like GNSS signals in places where conventional GPS is weak or unavailable — tunnels, underground carparks, logistics facilities and large indoor spaces. The company says it has validated the system in Korean locations including Namsan Tunnel, the Incheon Startup Park underground carpark and the Goyang Drone Anchor Center, and lists NET, KC, FCC and CE certifications.
The Singapore fit is unusually direct. Road tunnels such as the KPE and MCE, new underground rail including the Cross Island Line, and extensive basement carpark and logistics space all sit outside reliable satellite coverage, and any move toward autonomous or assisted vehicles makes continuous positioning a requirement rather than a convenience. The technical claim — that a company can simulate satellite signals indoors with enough accuracy for navigation — is the kind of thing that needs a local pilot to prove, which is exactly what IDCITI is seeking.
DeepCardio: AI reads the ECG you already have
DeepCardio’s SmartECG analyses a standard electrocardiogram to flag cardiac risk — notably atrial fibrillation and reduced cardiac function — without adding a separate test to the existing workflow. The company, incorporated in 2020, holds Korean MFDS approvals for SmartECG-AF (2024) and SmartECG-EF (2026), ISO 13485 and medical-device GMP certification, a GE HealthCare Korea partnership and a Sanofi MOU. It reports an AUC of 0.91 for SmartECG-AF in its 2024 approval data.
That number needs context. AI-ECG is one of the more mature corners of medical AI: Mayo Clinic’s foundational work reported an AUC of about 0.87 in 2019, Tempus has an FDA-cleared ECG-AF algorithm with Medicare coverage, and iRhythm, Philips and Anumana are all active. DeepCardio’s figure is in line with the field, not ahead of it — which is not a criticism, but a reminder that the differentiator is regulatory clearance in Korea and a workflow that reuses existing ECG data, not a breakthrough in accuracy. For Singapore, whose population is ageing and where cardiovascular disease is a leading cause of death, the appeal is that screening programmes already generate the ECG data the software reads.
JCHI Global: coatings that work in visible light
JCHI Global develops functional coatings and visible-light-responsive photocatalyst materials for buildings and infrastructure. Its stated functions include VOC and NOx reduction, antibacterial and deodorising performance, self-cleaning, heat reduction and thermal insulation. The distinguishing claim is that, unlike conventional photocatalysts that rely mainly on UV light, its materials stay active under visible light — widening indoor and outdoor applications. The company, founded in 2018, says it has moved into commercial validation in Korea through projects involving Hyundai Engineering & Construction and Korea Land & Housing Corporation (LH), with measurable surface-temperature reduction and a portfolio of patents and certifications.
Singapore is a plausible market: the Singapore Green Plan 2030, BCA Green Mark and urban-heat-mitigation priorities all create demand for coatings that cut surface temperatures and clean themselves. As with the other two, the claim is a Korean validation seeking a tropical one — and tropical conditions are exactly where a visible-light photocatalyst’s performance should be tested.
The reference-customer problem
What unites the three is not sector but stage. Each has moved past prototype into certified or field-tested products in Korea, and each is now looking for a first Singapore reference customer. That is the hardest step in deep-tech market entry: a local buyer wants evidence from a comparable deployment, and the company needs that first buyer to create the evidence. A limited proof of concept breaks the loop by lowering the risk on both sides — the buyer commits to a scoped trial, and the company gets a reference it can point to elsewhere in ASEAN. It is a slow process, and most delegations do not convert on a first visit; the ones that work tend to start with a narrowly scoped test rather than a full rollout.
For Singapore organisations, the release frames the entry points clearly: infrastructure pilots in GPS blind spots, clinical or screening validation for AI-ECG software, and testbeds for functional coatings in buildings or urban environments. Corporates, agencies, hospitals, system integrators and distributors can use the visit to assess technical fit before committing to a larger rollout — which is the right way to read a delegation with no announced deals. The three companies also illustrate how varied Singapore market entry can be. A positioning system needs infrastructure operators and system integrators; a medical-software company needs hospitals and regulators; a materials company needs developers and construction firms. The programme’s value is in matching each to the right local counterpart rather than treating them as a single cohort.
What to watch
For the three companies, the test is whether the visit produces a named pilot, and whether that pilot converts into a commercial reference. For KILSA and Incheon CCEI, the measure is how many of their cohorts reach that milestone rather than merely attending meetings, since the programme’s success will show in named pilots and signed references, not in the sheer number of meetings held. And, for Singapore partners, the practical questions are the same for any imported deep-tech: local validation, regulatory fit (especially for the medical device), and whether the economics hold under tropical conditions and local procurement rules. Those questions are the substance of Singapore market entry, and pilots answer them, not meetings.
What the announcement does and doesn’t establish
It establishes a scheduled visit, a named facilitator and three companies with Korean validation and clear Singapore use cases. It does not establish a deal, a partner or a signed pilot, and it does not reconcile its three-company framing with the broader programme KILSA has promoted. Read as a Singapore market entry signal rather than a commercial announcement, the release is a fair snapshot of the stage these companies are at — validated at home, unknown abroad, looking for the pilot that changes that.
The honest summary is that three Korean deep-tech firms are using Singapore as a gateway to ASEAN, with a business builder to open doors, and each is looking for the one thing they cannot buy: a first local customer. Whether they find one depends on pilots that have not yet been agreed. The next milestone to watch is a named pilot — the first hard evidence that any of this Singapore market entry work has landed. Until then, the three companies remain what the release calls them: pre-screened, validated at home, and still looking for their first local reference customer. The visit itself is the easy part; converting four days of meetings into a signed pilot is the real test the programme will be judged on.
Editor’s Note: This article draws on the company’s announcement and the participants’ public material, plus independent market data on AI-ECG and Singapore‘s infrastructure and green-building context. The technical, certification and clinical claims are company-reported; no deal, partner or value is disclosed, and the cohort size is not reconciled with the wider programme. No interview was conducted. See the source list in the publication package.